diabetes: GLP1 and SGLT2 decrease hyperkalemia risk
An article was just published showing that SGLT-2 inhibitors and GLP-1 receptor agonists decreased the likelihood of hyperkalemia in patients with type II diabetes: see GLP1 and SGLT2 dec hyperkalemia risk BMJ2024 in dropbox, or https://doi.org/10.1136/bmj-2023-078483 Details : -- a population-based study using claims data from Medicare and two large commercial insurance databases (Optum and Clinformatics Data Mart Database) in the US, with data from 2013-2022 -- adults were matched (by propensity score) who were newly started on SGLT-2 inhibitors versus DPP-4 inhibitors (n=778,908), GLP-1 receptor agonists versus DPP-4 inhibitors (n= 729,820) and SGLT-2 inhibitors versus GLP-1 receptor agonists (n= 873,460) -- patients with CKD stage 5 or ESRD were excluded from the analysis -- mean age 63, 50% female, 71% white/11% Black/10% Asian -- comorbidities: hypertension 79%, hyperlipidemia 78%, cardiovascular disease 30%, heart failure 8%, a...